PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.24%
Positive revenue growth while ADI is negative. John Neff might see a notable competitive edge here.
47.23%
Positive gross profit growth while ADI is negative. John Neff would see a clear operational edge over the competitor.
83.58%
EBIT growth above 1.5x ADI's 26.53%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
83.58%
Operating income growth above 1.5x ADI's 26.53%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
67.24%
Net income growth above 1.5x ADI's 2.02%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
72.41%
EPS growth above 1.5x ADI's 4.48%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
72.41%
Positive diluted EPS growth while ADI is negative. John Neff might view this as a strong relative advantage in controlling dilution.
18.75%
Share change of 18.75% while ADI is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
18.75%
Diluted share change of 18.75% while ADI is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-13.45%
Dividend reduction while ADI stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-62.05%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-67.65%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-45.13%
Negative 10Y revenue/share CAGR while ADI stands at 133.38%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-35.18%
Negative 5Y CAGR while ADI stands at 73.82%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-24.61%
Negative 3Y CAGR while ADI stands at 7.67%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
1782.46%
10Y OCF/share CAGR 1.25-1.5x ADI's 1596.09%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
-18.33%
Negative 5Y OCF/share CAGR while ADI is at 206.57%. Joel Greenblatt would question the firm’s operational model or cost structure.
14.77%
3Y OCF/share CAGR under 50% of ADI's 56.89%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-148.33%
Negative 10Y net income/share CAGR while ADI is at 2025.24%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-123.65%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-112.54%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
216.59%
Below 50% of ADI's 534.17%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
124.69%
Below 50% of ADI's 311.15%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
49.26%
Below 50% of ADI's 103.55%. Michael Burry suspects a serious short-term disadvantage in building book value.
-27.60%
Cut dividends over 10 years while ADI stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-7.16%
Negative 5Y dividend/share CAGR while ADI stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-5.66%
Negative near-term dividend growth while ADI invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
4.26%
Our AR growth while ADI is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
2.26%
We show growth while ADI is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-1.53%
Negative asset growth while ADI invests at 0.63%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-16.01%
We have a declining book value while ADI shows 1.41%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
0.24%
We have some new debt while ADI reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
1.57%
We increase R&D while ADI cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-11.96%
We cut SG&A while ADI invests at 1.59%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.